Company profile for Cyxone AB

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cyxone AB is a clinical biomedical company with a portfolio of immunomodulatory drugs to treat autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis. The company's drug portfolio is based on two technical pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typical of various immune disorders. Cyxone's technologies have the potential t...
Cyxone AB is a clinical biomedical company with a portfolio of immunomodulatory drugs to treat autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis. The company's drug portfolio is based on two technical pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typical of various immune disorders. Cyxone's technologies have the potential to address an unmet need by developing new, effective and safe drugs that can improve the quality of life for those affected by autoimmune diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
Adelgatan 21, 211 22 Malmö
Telephone
Telephone
+46 708 882 172
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.contractpharma.com/contents/view_breaking-news/2023-03-09/cyxone-streamlines-manufacturing-process-for-rabeximod/?widget=listSection

CONTRACT PHARMA
09 Mar 2023

https://ipohub.io/companies/cyxone-ab/news/nomination-committee-appointed-for-cyxone-annual-general-meeting-2023-081120221235

IPOHUB
08 Nov 2022

https://news.cision.com/cyxone/r/cyxone-will-leverage-ind-and-use-fda-pre-review-for-covid-19-phase-2-trial,c3421070

CISION
24 Sep 2021

https://news.cision.com/cyxone/r/cyxone-and-medical-university-of-vienna-announce-collaboration-to-study-broader-t20k-use-in-ms,c3377799

CISION
01 Jul 2021

https://news.cision.com/cyxone/r/cyxone-initiates-feasibility-preclinical-studies-to-optimize-path-forward-for-multiple-sclerosis-dru,c3342352#:~:text=Swedish-,Cyxone%20Initiates%20Feasibility%20Preclinical%20Studies%20to%20Optimize%20Path,Multiple%20Sclerosis%20Drug%20Candidate%20T20K&text=Cyxone%20announced%20today%20the%20initiation,Sclerosis%20drug%20candidate%20T20K%20forward.

CISION
06 May 2021

https://www.prnewswire.com/news-releases/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod-301209286.html#:~:text=STOCKHOLM%2C%20Jan.%2015%2C%202021,of%20Rabeximod%20in%20Covid%2D19.

PRNEWSWIRE
15 Jan 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty